Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible

Area of Science:

• Biostatistics
• Clinical Trial Analysis
• Epidemiology

Background:

• Understanding the distribution of treatment effect sizes is crucial for clinical trial design and interpretation.
• Previous research has explored treatment effect magnitudes, but a comprehensive analysis of
• large
• dramatic
• effects using robust statistical modeling is needed.

Purpose of the Study:

• To analyze the distribution of large and
• dramatic
• treatment effects observed in clinical research.
• To model these effects using Pareto distribution for both randomized controlled trials (RCTs) and non-randomized studies (NRS).

Main Methods:

• Pareto distribution modeling was applied to data from 3,486 RCTs (1,532,459 patients) and 730 NRS (1,650,658 patients).
• The Pareto α parameter was calculated to characterize the tail of the distribution for various minimum odds ratios (ORmin).
• Goodness-of-fit was assessed using the Kolmogorov-Smirnov test.

Main Results:

• Pareto distribution modeling showed a good fit for RCT treatment effects (α = 2.32) and NRS effects (α = 1.91 for ORmin ≥2).
• For RCTs, the 99th percentile odds ratio was 32.7 (actual: 25, RR = 7.1), with a maximum observed OR of 121 (RR = 11.45).
• For NRS, the 99th percentile odds ratio was 315 (actual: 294, RR = 13), with a maximum observed OR of 1473 (RR = 66).

Conclusions:

• Observed effect sizes in RCTs and NRS show considerable overlap.
• Large treatment effects are infrequent in both study types.
• There is no definitive threshold for
• dramatic
• effects that would eliminate the need for future RCTs.